Esomifyl SL 75mg/40mg Capsule SR is a combination medication containing Levosulpiride 75mg and Esomeprazole 40mg, formulated as a sustained-release capsule. Levosulpiride is a selective dopamine D2 receptor antagonist with prokinetic and antiemetic properties, primarily used to enhance gastrointestinal motility and treat functional dyspepsia, gastroesophageal reflux disease (GERD), and related disorders. Esomeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thereby promoting mucosal healing and symptom relief in acid-related conditions. The combined action of Levosulpiride and Esomeprazole in Esomifyl SL provides synergistic benefits in managing upper gastrointestinal tract disorders characterized by impaired motility and excessive acid secretion. This combination is particularly useful in patients with GERD, erosive esophagitis, and functional dyspepsia who require both acid suppression and improved gastric emptying. The sustained-release formulation ensures prolonged therapeutic effects, enhancing patient compliance by reducing dosing frequency. Esomifyl SL should be used under medical supervision, with caution advised in patients with renal or hepatic impairment, and contraindicated in individuals with hypersensitivity to either component. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances.